Cogent Biosciences, Inc. COGT Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s operating lease right-of-use asset amortization?
- Cogent Biosciences, Inc. (COGT) reported operating lease right-of-use asset amortization of $529K in Q1 2026.
- How has Cogent Biosciences, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Cogent Biosciences, Inc.'s operating lease right-of-use asset amortization increased by 6.2% year-over-year, from $498K to $529K.
- What is the long-term trend for Cogent Biosciences, Inc.'s operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s operating lease right-of-use asset amortization has grown at a -26.3% compound annual growth rate (CAGR), from $5.04M to $2.02M.